We are international
Donate
TEXT SIZE   


National Cancer Institute Leukemia, Lymphoma And Myeloma Progress Review Group (PRG)
07.21.01
The following is a summary of the recommendations of the Leukemia, Lymphoma and Myeloma Progress Review Group (LLM PRG). You can view the entire report by clicking here or on the PDF link to the right.

In 2000, the National Cancer Institute (NCI) convened a special blue ribbon panel of researchers, clinicians, industry representatives, government officials and advocates to assess the NCI research program in leukemia, lymphoma and myeloma and to develop recommendations for the future.

This group, the Leukemia, Lymphoma and Myeloma Progress Review Group (LLM-PRG) identified challenges and opportunities for research on hematological cancers. The recommendations of the LLM-PRG emphasize strategies for accelerating the development of new treatments for the hematological cancers. Of great interest to the advocates were those collaborative research initiatives aimed at reducing substantially the time for drug development.

The LLM-PRG proposed high-priority research initiatives to:

  1. Understand the etiology of leukemia, lymphoma and myeloma.
  2. Identify the mechanisms responsible for genome instability, chromosome translocations, and other mutations in hematological malignancies.
  3. Study the complex problem of tumor-host interactions in leukemia, lymphoma and myeloma.
  4. Develop a molecular definition of hematological cancers to aid in diagnosis and treatment.
  5. Initiate new partnerships among NCI, academia, advocates, cooperative groups, the Food and Drug Administration (FDA) and industry to expedite drug development
  6. Improve informational and educational materials for individuals with leukemia, lymphoma and myeloma to assist tem in making decisions about their care.

The panel also proposed a new program, called the Cancer Translational Research Allied Consortium (C-TRAC), to encompass the whole spectrum of drug development and to shorten the drug development time from 5-10 years to 2 years.

Leukemia, lymphoma and myeloma advocates strongly support the research plan outlined in the report of the LLM-PRG and urge congress to require that NCI develop, by December 31, 1001, a budget and business plan to ensure that the LLM-PRG recommendations are implemented.


 related articles